リツキシマブ併用化学療法後のＢ型肝炎ウイルス再活性化への対策

DOI Web Site 参考文献5件

書誌事項

タイトル別名
  • Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab
  • リツキシマブ ヘイヨウ カガク リョウホウ ゴ ノ Bガタ カンエン ウイルス サイカッセイカ エ ノ タイサク

この論文をさがす

説明

Reactivation of hepatitis B virus (HBV) has been recognized as one of the most serious complications in patients receiving chemotherapy with rituximab. From October 2007 to December 2008, rituximab was administered to 123 B-cell lymphoma patients in our institute. Four patients with positive hepatitis B surface antigen (HBsAg) received preemptive entecavir, and none of them developed HBV reactivation. For 26 patients whose hepatitis B surface antibody (HBsAb) and/or hepatitis B core antibody (HBcAb) were positive, HBV-DNA was monitored for one year after completion of chemotherapy. During this period, HBV reactivation was observed in two patients. Hepatitis was prevented in one patient by the administration of entecavir at the time HBV-DNA turns positive. Another developed de novo hepatitis B due to failure of monitoring. Preemptive entecavir for HBsAg positive patients and HBV-DNA monitoring for HBsAb and/or HBcAb positive patients seem to be effective.

収録刊行物

  • 臨床血液

    臨床血液 51 (3), 213-215, 2010

    一般社団法人 日本血液学会

参考文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ